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8SUMMARY 
This thesis is based on three published papers that illuminate different aspects of 
prescribing quality and drug use in older patients who receive home nursing services 
or live in nursing homes.  
Persons older than 65 years account for about 15% of the Norwegian 
population, but use almost half of all prescribed drugs. Age-related and physiological 
changes affect drugs’ pharmacokinetics (absorption, distribution, metabolism and 
elimination). For example, a reduction of muscle mass and an increase in fat 
percentage will allow an accumulation of fat-soluble drugs, while reduce renal 
function will influence the pharmacological response and the elimination of drugs. 
Pharmacodynamic changes include up or down-regulation of receptors and altered 
receptor sensitivity. Along with reduced homeostasis, these factors puts older patients 
at risk of adverse drug events, possibly resulting in reduced quality of life, 
hospitalization and in worst case death. It is therefore important to identify and prevent 
inappropriate prescribing and drug-related problems. 
An explicit method for assessing prescribing quality is to compare patients' 
medication lists with a predefined list of drugs considered to be inappropriate for use 
in older patients. Such lists are eligible for screening of large populations, but they 
rarely take the patients' clinical conditions into consideration. Another method is to 
consider drug-related problems by conducting a systematic review of patients' overall 
drug use, taking their clinical conditions into consideration. Although systematic 
medication reviews are suitable for multidisciplinary collaboration between 
physicians, nurses and pharmacists, little knowledge exists about how this 
collaboration works and how it is perceived. 
The purpose of Paper I was to examine the quality of drug prescribing in older 
patients in nursing homes and home nursing services receiving multidose dispensed 
drugs, by means of explicit quality indicators. We studied 11 254 patients, of whom  
2 986 were living in nursing homes, and 8 268 received home nursing services. On 
average, both patient groups were prescribed 5.7 regular multidose dispensed drugs. 
While relatively more patients in nursing homes used psychotropic drugs, those in 
9home nursing service used cardiovascular drugs more frequently. Inappropriate drug 
use was found in 31% of patients in nursing homes and in 25% of home nursing 
service patients. Concomitant use of three or more psychotropic drugs and/or opioid 
drugs caused most problems. Potentially serious drug-drug interactions were found in 
~ 10% of patients. 
The aim of Paper II was to test a multidisciplinary model to identify and 
resolve drug-related problems in nursing homes. Three pharmacists conducted 
systematic medication reviews in 142 patients. A total of 719 potential problems was 
presented to and discussed with the patients’ physician and primary nurse at case 
conferences, of which 504 drug-related problems were acknowledged by the 
multidisciplinary team. Most problems were associated with unnecessary drug use (n = 
194) and the need for monitoring (n=68). Paracetamol, lactulose and zopiclone caused 
most drug-related problems. 94% of the problems were resolved within the next three 
weeks. The intervention resulted in an average reduction of 1.5 prescribed drugs per 
patient. 
In Paper III, we explored how physicians and nurses working in nursing homes 
and hospitals experienced multidisciplinary collaboration with pharmacists to optimize 
drug therapy in older patients. By interviewing physicians and nurses, we found that 
these two professions had different expectations in relation to pharmacist 
contributions. While physicians felt that the pharmacists questioned their drug therapy 
choices, nurses experienced that focus changed away from their tasks, and towards 
drug-related issues. Both professions expressed, however, that the presence of 
pharmacists resulted in a positive focus on prescribing quality and quality 
improvement. However, before implementing this service in NHs, there is a need to 
make an organisational frame for this collaboration to support the professional role of 
the pharmacist.  
This thesis shows that the quality of drug treatment in the studied patient groups 
is sub-optimal. Many older patients in nursing homes and those receiving home 
nursing services are exposed to potentially inappropriate medications. Multi-
disciplinary cooperation between physicians, nurses and pharmacists can be developed 
in order to identify inappropriate drug use, and to resolve drug-related problems. 
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SUMMARY IN NORWEGIAN (sammendrag)  
Avhandlingen er basert på tre publiserte artikler som belyser ulike aspekter ved 
forskrivningskvalitet og legemiddelbruk hos eldre pasienter som mottar 
hjemmesykepleie eller som bor på sykehjem.  
Eldre over 65 år utgjør i dag ca 15 % av den norske befolkning, men står for 
bruken av nesten halvparten av alle forskrevne legemidler. Aldersrelaterte fysiologiske 
forandringer kan påvirke legemidlenes farmakokinetikk (absorpsjon, distribusjon, 
metabolisme og eliminasjon). Eksempelvis vil redusert muskelmasse og økt fettprosent 
medføre en opphopning av fettløselige legemidler, og redusert nyrefunksjon kan 
påvirke farmakologisk respons og utskillelse av legemidler. Farmakodynamiske 
endringer inkluderer blant annet opp- eller nedregulering av reseptorer og endret 
reseptorsensitivitet. Samtidig som homeostasen reduseres medfører disse faktorene en 
økt risiko hos eldre for uhensiktsmessige legemiddeleffekter som kan resultere i 
redusert livskvalitet, sykehusinnleggelser og i verste fall død. Det er derfor viktig å 
identifisere og forebygge uhensiktsmessig forskrivning og legemiddelrelaterte 
problemer.    
En eksplisitt metode for å vurdere forskrivningskvalitet er å sammenlikne 
pasientens legemiddelliste mot en forhåndsdefinert liste over legemidler som er ansett 
uhensiktsmessige for bruk hos eldre. Slike lister er egnet for å screene store 
populasjoner, men tar imidlertid sjeldent høyde for pasientens kliniske tilstand. En 
annen metode er en systematisk gjennomgang av pasientens samlede legemiddelbruk 
hvor man benytter eksplisitte kategorier for legemiddelrelaterte problemer (indikasjon, 
legemiddelvalg, dosering, bivirkning, interaksjon, bruk), og hvor pasientens kliniske 
tilstand tas med i vurderingen. Denne metoden egner seg for tverrfaglig samarbeid 
mellom leger, sykepleiere og farmasøyter. Vi vet derimot lite om hvilke erfaringer og 
oppfatninger helsepersonell har, samt hvordan et slikt samarbeid fungerer.    
 Formålet med artikkel 1 var å undersøke legemiddelbruk og kvalitet på 
legemiddelforskrivning hos eldre personer i sykehjem og i åpen omsorg som mottar 
multidosepakkede legemidler, basert på eksplisitte kvalitetsindikatorer. Vi screenet 
legemiddellistene hos 11 254 pasienter, hvorav 2 986 var innlagt i sykehjem og 8 268 
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mottok hjemmesykepleie. I gjennomsnitt brukte begge pasientgruppene 5.7 multidose-
pakkede legemidler på fast, daglig basis. Mens psykofarmaka ble hyppigere forskrevet 
til sykehjemspasienter, fikk flere pasienter i åpen omsorg legemidler for kardio-
vaskulære lidelser. Uhensiktsmessige legemidler ble brukt av 31 % av sykehjems-
pasientene og 25 % av pasientene som mottok hjemmesykepleie. Samtidig bruk av tre 
eller flere psykofarmaka og/eller opioide legemidler forårsaket flest problemer. 
Potensielt alvorlige legemiddelinteraksjoner ble funnet hos ca 10 % av pasientene.    
Hensikten med artikkel 2 var å utprøve en tverrfaglig modell for å identifisere 
og løse legemiddelrelaterte problemer i norske sykehjem. Tre farmasøyter foretok 
systematiske legemiddelgjennomganger hos 142 pasienter. I alt 719 potensielle 
problem ble presentert for og diskutert med pasientens lege og primærsykepleier på 
previsitten, hvorav 504 legemiddelrelaterte problem ble anerkjent av det tverrfaglige 
teamet. Flest problemer var knyttet til unødvendig legemiddelbruk (n=194), og behov 
for monitorering (n=68). Paracetamol, laktulose og zopiclone var oftest innblandet i 
legemiddelrelaterte problemer.  94 % av problemene ble løst i løpet av de påfølgende 
tre ukene. Intervensjonen resulterte i en gjennomsnittlig reduksjon av 1,5 forskrevne 
legemidler per pasient. 
I artikkel 3 utforsket vi hvordan leger og sykepleiere erfarte tverrfaglig 
samarbeid med farmasøyter. Gjennom intervju fant vi at disse to yrkesgruppene hadde 
ulike forventinger til hva farmasøyten skulle bidra med. Mens legene erfarte at 
farmasøytene utfordret dem på spørsmål angående legemiddelterapi, erfarte syke-
pleierne at fokus ble endret bort fra deres oppgaver, og mot farmakoterapeutiske 
problemstillinger. Begge yrkesgruppene uttrykte at farmasøytens nærvær satte fokus 
på og hevet forskrivningskvalitet. Likevel, før en slik tjeneste kan implementeres i 
sykehjem, bør det utvikles en organisatorisk ramme som ivaretar farmasøytenes 
profesjonelle rolle i dette samarbeidet. 
Denne avhandlingen viser at kvaliteten på legemiddelbehandling hos eldre 
pasienter ikke er optimal. Mange eldre i sykehjem og åpen omsorg bruker potensielt 
uhensiktsmessige legemidler. Tverrfaglig samarbeid mellom leger, sykepleiere og 
farmasøyter har potensial for å videreutvikles med tanke på å avdekke uhensiktsmessig 
legemiddelbruk, samt løse legemiddelrelaterte problemer.      
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INTRODUCTION          
Older patients receiving home nursing services (HNS) or living in nursing homes (NH) 
commonly suffer from complex health problems and often use multiple medications 
concomitantly. Age-related changes affecting pharmacodynamic and pharmacokinetic 
properties, and co-morbidity, are great challenges for optimal drug therapy and put 
frail and vulnerable patients at increased risk of adverse drug events (ADE) [1], 
hospitalization [2] and death [3]. The lack of evidence-based treatment 
recommendations for older people, and the fact that most drugs are tested (pre-
marketing studies) in younger individuals, makes the situation even more difficult. 
Nevertheless, medications are the most commonly used treatment modality for older 
patients; emphasising the need to assess and improve the quality of drug therapy. 
During the last years, patient-centered clinical pharmacist services have gradually been 
implemented in Norwegian hospitals. In contrast, similar services have not been put 
into practice in primary health care.  
This thesis aims to assess the quality of drug utilization among older people in 
two primary care settings, i.e. HNS and NHs. In the introduction, HNS and NHs in 
Norwegian primary health care system are outlined. Then, a short description of drug 
utilization and quality of drug prescribing in older patients is provided. Finally, clinical 
pharmacist services and pharmacists’ involvement in multidisciplinary teams are 
briefly described. Two comprehensive quantitative studies and one supplementary 
qualitative study have been performed. The first study examines drug use by means of 
explicit prescribing quality indicators. The second study investigates drug-related 
problems in NH patients based on systematic multidisciplinary medication reviews. 
The third study explores physicians’ and nurses’ experiences of collaborating with 
pharmacists.  
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The health care system for older patients  
Figure 1. Population projection for Norway [4] 
(Reprinted with permission) 
Increased life expectancy combined with large birth cohorts following World War II 
until 1975, is leading to increasing numbers and proportions of older people in high 
income countries in years to come, Figure 1. Life expectancy has increased 
continuously for the last two hundred years. Today’s newborn girls and boys have an 
average life expectancy of 83 and 79 years, respectively [4]. Population projections for 
the year 2060 estimate about 1.5 million people 67 years old compared to 625 000 in 
2010 [4]. In addition, the proportion of elderly 80 years increases as well (Figure 1). 
The aging population represents a major challenge to our country’s health care system. 
In the present work older people are defined as those 65 years.  
Ageing is accompanied by age-related changes and health problems. Functional 
decline increases older peoples’ need for health care services. Both somatic diseases 
such as cardiovascular and musculoskeletal morbidity and cancer, as well as mental 
disorders such as dementia, depressions and anxiety are prevalent [4-6]; illustrating a 
range of complex illnesses among older patients.  
The municipalities in Norway are obliged by law to provide health care services 
to their inhabitants with essential needs. The services comprise two levels; HNS is 
provided to people living in their own home or in residential care facilities; 
institutionalized services comprise people living in NHs and homes for the aged. From 
1996 to 2010, the capacity in homes for the aged has been reduced from 9 500 to 1 600 
places [4]. A politically intended strengthening of HNS and reduction of the capacity 
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in homes for the aged, has been leading to that older people reside at home longer than 
before. An application for HNS or NH placement is put forward to the local health 
authorities, usually by patients’ relatives. The municipalities decide on allocation of 
HNS, and on temporary or permanent placement in an institution. Definite inclusion 
criteria do not exist. The HNS and NH settings are devoted attention in this thesis. 
  
Home nursing service    
HNS provide professional health care to patients with widely varying needs. The 
majority of users are 65 years, with a range of somatic and mental disorders and 
symptoms. The number of older persons receiving HNS approximated 130 000 in 
2010 [4]. During the last two decades the demand for this service has increased, in 
particular among individuals younger than 65 years [7]. The annually net increase 
during the last years has been estimated to 8-9% [6]. 
HNS are organized and financed by the municipalities, and carried out by 
licensed nurses, auxiliary nurses and care-workers. In addition, unskilled personnel 
account for a significant proportion of the staff, ranging from 21% during weekdays to 
34% at weekends [8]. HNS comprise tasks such as medication management including 
collecting prescriptions at local pharmacies, filling of one-week drug dispensers, 
measuring blood glucose, injection of insulin, pain management (i.e. pain pump), and 
wound care. Some municipalities also offer physical therapy or occupational therapy, 
for instance during rehabilitation after stroke or surgery. 
Approximately 99% of the Norwegian population is contracted to a specific 
physician through the Regular General Practitioners (GP) Scheme that was 
implemented in 2001. GPs are responsible for older patients’ medical assessment and 
treatment, including drug therapy and referral to specialist health care. Prescriptions 
are usually dispensed for 3-months supply from local pharmacies and/or delivered as 
multi-dose dispensed drugs (MDD). Although the municipalities are required to 
facilitate multidisciplinary collaboration between GPs and HNS, it is rarely put into 
the system. 
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Nursing homes 
In Norway, eligible patients for NH placements are those with severe functional 
impairment and/or in need of more continuous health care services than offered by the 
HNS, i.e. 24-hour nursing care. NHs are intended to constitute both a home and a 
health care institution at the same time. The mean age of NH patients is on average 84 
years, and more than 70% are women [9]. Mean life expectancy on NH admittance is 
shorter than 2 years, and approximately 40% of all deaths occur in this setting [10], 
similar to all-cause mortality in hospitals [4].  
  In 2010, the almost 900 NHs had a total capacity of 41 000 beds [4], of which 
80% were long-term care beds in regular wards or in special care units for patients 
with dementia. The remaining 20% comprised respite care, rehabilitation or palliative 
care. About 220 000 people were 80 years or older; NH coverage for this population in 
Norway was about 19% [4], exceeding proportions in Sweden (16%), Denmark (13%) 
and The Netherlands (9%). The Norwegian Government aims to increase the capacity 
by establishing 12 000 new places by 2015 [11]. 
NHs in Norway are heterogeneous with regard to size, ward types and services 
provided. These differences exist as the municipalities vary in terms of size (Oslo has 
600 000 inhabitants, Røst in Lofoten about 605), population demographics and health 
care needs [4]. However, most patients entering the NHs have severe physical and/or 
mental impairment, and are in need of care around the clock over a shorter or longer 
period of time.  
Known predictors for institutionalization are dementia in persons living alone, 
behavioural and psychological symptoms of dementia, and patient carers with mental 
problems [12]. About 80% of NH patients suffer from moderate to severe dementia, 
and 72% have clinically significant neuropsychiatric symptoms [9]. Another challenge 
for NHs is that the number of patients with special care needs such as dementia care or 
palliative care outweighs the present capacity of specialized health care services. 
Nursing care is normally provided by licensed nurses (20% of nursing staff), auxiliary 
nurses, care workers and unskilled personnel. Other health care professions such as 
physiotherapists and occupational therapists are scarce in NHs [10].  
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Medical care is most commonly provided by part-time contracted GPs who are 
working in a NH one or two days weekly. Larger institutions in bigger cities may 
employ physicians full-time. The physicians are responsible of diagnostics and 
treatment including drug therapy, while nursing staff is setting the agenda. Normally, 
initiation and adjustment of drug therapy is discussed between physicians and nurses at 
regular patient-centred case conferences. Electronic patient record systems with good 
functionality are not yet implemented in Norwegian NHs. Drugs are requisitioned and 
received directly from pharmaceutical wholesalers or pharmacies, either in separate 
packages or as MDD. Only licensed nurses are allowed to conduct drug dispensing, 
usually into one-week pill dispenser, while auxiliary nurses and care workers may 
administer drugs to the patients. Pharmacists have until now not been directly involved 
in drug therapy in the NH multidisciplinary team [10, 13].  
Drug use in older patients 
Older persons constitute about 15% of the total Norwegian population, and are 
responsible for almost 50% of the total prescribed drug consumption [14]. Drug 
therapy is a cornerstone of medical care for older patients with complex health 
problems and severe functional and/or mental impairment.  
A multicenter study in eight European countries including older patients 
receiving home care services reported that more than half of the patients used six or 
more drugs [15]. Another study comprising 786 older patients receiving HNS 
identified a mean of eight drugs per patient, while 40% of the patients used nine or 
more drugs concomitantly [16]. Comparable drug utilization studies from Norwegian 
HNS are sparse. 
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Table 1. Average regular drug use among older patients in nursing homes  
Author Year Country       N 
Average number of 
regular drugs used 
Ruths [17] 2003 Norway 1 354 5.0 
Snowdon [18] 2006 Australia 3 054 5.4 
Bergman [19] 2007 Sweden 7 904 9.0 
Rytter [20] 2007 Norway 1 053 7.0 
Hosia-Randell [21] 2008 Finland 1 987 7.9 
Olsson [22] 2010 Sweden 2 938 8.5 
The five most frequently used drug groups in Norwegian NHs, classified according to 
the Anatomical Therapeutic Chemical (ATC) system [23], were laxatives (60% of the 
patients), diuretics (34%), antidepressants (31%), analgesics (28%) and acetylsalicylic 
acid (23%) [24]. Drug utilization studies of older patients in NHs during the last ten 
years suggest an increase in number of regular drugs prescribed, Table 1 [17-22, 25, 
26]. Not included in these numbers are pro re nata (p.r.n.) medication, also referred to 
‘as required’ or ‘as needed’ medications, i.e. drugs prescribed on each patient’s drug 
list, or drugs given according to NHs’ individual guidelines for use of p.r.n. 
medications. Two Scandinavian studies report a mean of 2.1-2.5 p.r.n. medications 
prescribed per patient [20, 22]. According to a Norwegian study the most frequently 
prescribed p.r.n. medications were: paracetamol, metoclopramide, zopiclone, glyceryl 
trinitrate and diazepam [27]. NHs’ individual p.r.n. guidelines, issued by the NH 
physician to nursing staff recommend drugs for treatment of minor already diagnosed 
medical problems such as pain, nausea, sleeping disorders, angina or constipation, 
when the physician is not available. Concerns regarding the quality of p.r.n. 
administration guidelines have been put forward. Guidelines of low quality impede the 
nurses’ decision process whether to give drugs or not, and may subsequently 
jeopardize patient safety [27].  
Polypharmacy addresses the use of multiple drugs by one patient, normally 
suffering from more than one illness. The term is often associated with drug use in 
older persons [28]. Several definitions exist: i] concomitant use of five or more drugs 
[29], although some NH studies have set a cut off of nine drugs [30, 31], ii] 
unnecessary drug use, i.e. use of more medications than clinically indicated [32, 33], 
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or iii] the use of at least one inappropriate drug [34]. To avoid confusion, the neutral 
term ‘multiple drug use’ is applied throughout this thesis. 
Challenges for drug treatment  
There are many challenges at the patient level regarding the quality of drug prescribing 
and drug use [35]. Age-related changes, inadequate prescribing and incorrect use are 
all considered to reduce overall quality of drug treatment. Physiological alterations 
lead to pharmacological change and in particular affect drugs’ pharmacokinetic 
properties. While age seldom influences drug absorption, the distribution, metabolism 
and elimination are often affected and require dose alterations [36]. In addition, 
changed body composition, e.g. increased fat:water ratio, potentially results in 
accumulation of lipid-soluble drugs. The annually 1% decline in renal function from 
young adult age reduces the elimination of water-soluble drugs, underlining the 
importance of monitoring renal function. Simultaneously, pharmacodynamic 
alterations, such as up or down regulation of receptors, modified receptor-sensitivity 
and reduced homeostatic mechanisms affect older patients. In consequence, enhanced 
drug effects pose older patients at increased risk of ADR such as constipation, falls, 
fatigue and confusion [37, 38].  
At the organization level, challenges include discrepancies between drug lists 
kept by patients’ regular GP and HNS [39], and sub-optimal flow of information 
between hospitals and primary health care [40, 41], due to sub-optimal communication 
and collaboration between  different health care levels [42]. In addition, problems with 
self-medication by either using over-the-counter medications [43], or non- compliance 
of various reasons [44], are prevalent. Non-compliance may lead to reduced 
therapeutic outcome or adverse drug effects, which are reported to cause 10% of 
hospital admissions. However, it should be noted that old age is not necessarily 
associated with poor compliance [45]. 
20
Drug-drug interactions  
Multiple drug use is associated with increased risk of drug-drug interactions (DDIs) 
[46-48]. A DDI can be defined as; “The action of a drug that may affect the activity, 
metabolism, or toxicity of another drug” [49]. DDIs can be divided into 
pharmacodynamic interactions; two drugs competing for the same target receptor, or 
pharmacokinetic interactions; one drug altering the metabolism of another [50], thus 
lowering or increasing drug effects. However, the clinical consequences of DDIs are 
often difficult to predict. 
Studies report 25% prevalence of DDIs in older NH patients [31] and 46% in 
geriatric outpatients [51]. Comparable statistics for HNS could not be identified. Drugs 
commonly involved in DDIs include diuretics, NSAIDs, ACE-inhibitors, oral anti-
diabetics, calcium-channel blockers, anticoagulants and beta-blockers [52].  Multiple 
drug use combined with age-related physiological changes put older patients at 
increased risk of DDIs. The probability of experiencing DDIs was more than five 
times higher in patients receiving five or more regular drugs, compared to those using 
less than three drugs concurrently [53]. Therefore, older persons who use multiple 
drugs should be carefully monitored [52].      
 There has been progress in terms of identifying DDIs from patients’ drug 
records. Moving from using works of reference, like the book ‘Stockley’s Drug 
Interactions’ [50], to online web-based tools [50, 54, 55], or works of references 
implemented in the computer software at GPs’ offices or pharmacies considerably ease 
the task. This development allows a systematic approach to avoid preventable DDIs. In 
Norway, GPs are responsible for the total overview of their patients’ drug use; most 
GPs and all pharmacies have implemented a DDI-checker into their electronic patient 
medical record system. Patients can freely choose which pharmacy they want to 
dispense their prescription drugs, however transfer of patient or drug information 
between pharmacies is not allowed. For patients to gain full benefit of the systematic 
DDI-checker, they must be regular customers. In most NHs, however, electronic 
patient record systems with integrated tools to check for DDIs are not available. 
Although the functionalities of such databases differ, they are usually convenient in 
use. Still, it is important to be aware of the limitations of DDI-checkers. For instance, 
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in the Norwegian ‘Drug information database’ (DRUID) [54], in general only 
previously documented interactions appear; meaning that suspected interactions based 
on similarities such as metabolism are not included [56]. Neither will the co-
prescribing of two generic drugs such as Furix® and Diural® (furosemide), nor two 
chemically related substances such as Furix® and Burinex® (bumetanide). Therefore, 
basic pharmacological knowledge and skills are important to maintain, both for 
physicians and pharmacists. A strategy to prevent DDIs is to perform a DDI-check 
whenever new drugs are prescribed or released, however, independent critical thinking 
is also necessary [56].  
Multi-dose dispensed drugs 
In 2002 the Norwegian Board of Health Supervision reported problems in the 
medication management in NHs and HNS and depicted that about 12% of the errors 
was related to the dispensing phase and 38% to the administering phase [57]. In 
attempt to increase the quality of drug dispensing and administering, multidose 
dispensing drug (MDD) systems were implemented. In 2009, approximately 35 000 
people in Norway received their drugs as MDD [58], mostly older persons receiving 
HNS or living in NHs. The MDD system is an automated system, dispensing only per 
oral solid drug formulations (tablets and capsules) by and large prescribed for regular 
use. Consequently, other drug formulations and p.r.n. medications are not dispensed as 
MDD; a second dispensing system is needed for managing p.r.n. medications, 
injectables, inhalators, ointments and mixtures, as well as drugs that needs close 
monitoring such as antibiotics and warfarin.  
The implementation of MDD was intended to increase overall quality of the 
drug administration process; hereby reducing nurses’ workload for drug dispensing 
and liberating time for patient care, reducing discharge of drugs from stocks, and 
maybe most importantly preventing dispensing errors [59]. On the other hand, 
questions regarding how MDD affects overall prescribing quality, the impact of 
excluding nurses from drug dispensing, and dispensing quality for drugs not comprised 
by the MDD system. One study suggests that MDD users are more prone to receive 
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inappropriate drugs [60]. In addition, discrepancies have been found between GPs’ and 
HNS’ MDD lists [61].  
Quality concerns regarding drug treatment in HNS and NHs are similar. Compared to 
HNS, coordination of services is probably better in NHs due to the organizational 
framework. In 2008-2010 the Norwegian Board of Health Supervision performed a 
system audit of drug treatment in NHs, and concluded that patient safety may be 
threatened. Deviations were found in 51 of the 67 inspected NHs. The identified 
problems included physician time constraints regarding follow up of patients’ drug 
treatment, lack of time and competence among nursing personnel to observe and report 
drug effects and ADRs, and NHs management lacking overview of risk factors related 
to drug treatment [62]. Provided the impending increase in institutional capacity [11], 
it is important to implement quality systems to support health professionals 
responsible of drug treatment in NHs.  
Drug prescribing quality for older patients 
Pharmacoepidemiology consist of the words pharmacology and epidemiology and 
deals with ‘the use and effects of drugs in a large number of persons’ [63]. 
Pharmacoepidemiological methods are suitable to measure the quantity of drug use in 
populations and how this quantity compares between populations [64]. Drug databases 
are often sources for such studies, like for instance the Norwegian prescription 
database [65]. Different study designs can be used to assess drug utilization and to 
improve the quality of drug prescribing in older persons. 
Descriptive studies are conducted to map drug use in populations according to 
number and proportion of users, and distribution regarding age, gender, geography, 
and other determinants. Such studies are often performed at a particular point of time 
(cross-sectional) or longitudinal (prospective or retrospective). For instance, the design 
can be used to describe the prevalence of potentially inappropriate medications (PIMs) 
[66].  
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Analytical studies assess how drug utilization is associated with factors like 
demography, geography, disease or other drugs. Analytical studies can either be 
observational (e.g. case-control or cohorts) or interventional (e.g. randomised control 
trials). For instance, interventional studies are conducted to investigate the effect of 
certain drugs on a certain disease, or the consequences of educational programmes on 
prescribing quality. Studies may be conducted with control groups, or with before-
after design. The latter design has previously been used to evaluate the effects of 
systematic medication reviews [67].   
Qualitative methods based on interviews explore aspects that are difficult, or 
even impossible to obtain quantitatively. In particular, the method is useful to explore 
beliefs, experiences and feelings [68]. Morgan emphasizes the importance of 
combining quantitative and qualitative research as it follows the principle of 
complementarity. However, one needs to decide in what sequence the methods should 
be applied [69]. To improve quality of drug treatment in older patients, qualitative 
methods like focus group interviews or individual interviews may help to explore 
interactions between e.g. health professions [70]. The method may also be applied on 
patients and their relatives to explore their thoughts and experiences regarding drug 
treatment and high compliance.  
Prescribing quality indicators 
What constitutes good prescribing? According to Barber, at least four different 
domains need to be judged [71]. First, one has to respect the patients’ autonomy and 
choice. Second, one should seek to maximize effectiveness of drug therapy. Third, the 
risk of treatment must be minimized, and fourth, total costs should be kept low, both 
for patients and society.  
Prescribing quality indicators (PQI) may be defined as follows; “A measurable 
element of prescribing for which there is evidence or consensus that it can be used to 
assess the quality, and hence change in the quality, of treatment provided” [72]. It is 
normal to refer to indicators as implicit; which are judgement based, or explicit; which 
are rigid standard indicators. The choice of indicator depends on the purpose. For 
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instance, when evaluating specific medicines or group of medicines, explicit criteria 
can be useful [24].  
Prescribing is a complicated task. When dealing with PQI the terms 
“appropriate” and “inappropriate” are often used to describe the quality of prescribing. 
There exists no rationale behind choosing one over the other, but some prefer 
“appropriate” because the term implies achievable quality in practice [73]. 
Inappropriate prescribing, on the other hand, may potentially be easier to detect, 
because violating only one of the four domains may trigger a result.  
Different indicators to assess the quality of drug therapy have been elaborated; a 
selection is presented in Table 2. Most indicators’ main purpose is to examine the 
prevalence of PIMs used by older patients. However, the Screening Tool to Alert 
doctors to the Right Treatment (START) is intended to systematically identify omitted 
drugs in clinical practice [74], while the Australian Prescribing Indicators Tool is more 
comprehensive in terms of medications considered inappropriate, recommendations 
for treatment of certain diseases, drugs requiring monitoring or those causing DDIs 
[75]. When selecting tools to assess the quality of drug prescribing, one should 
consider availability of clinical information, convenience of use, as well as clinical 
relevance for the studied population [76]. 
Explicit criteria can be used to identify PIMs. An advantage of such criteria is 
that they are easy to apply on large datasets, like the Norwegian prescription database 
[65]. However, a major drawback is that they seldom take into account clinical 
information such as diseases [73]. Another disadvantage is that they cannot 
automatically be transferred to other countries, as indicators’ applicability relies on 
drug therapy traditions and correspondence with national drug formularies. This is also 
the main reason for developing national indicators [75, 77]. In later years, however, it 
may look like that national and international guidelines are merging [77-80]. 
Furthermore, explicit criteria are usually developed from expert opinions, using the 
modified Delphi method [81], and hence not evidence based. Last, maintenance of the 
criteria must be performed regularly to avoid conflicts with current treatment 
guidelines [82]. 
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The Beers list is the most frequently used criteria set to assess PIMs worldwide, 
but for reasons stated above, national indicators have been developed in several 
countries during the last decade, Table 2. Studies encountering PIMs based on Beers 
criteria report prevalence among older patient to range from 18 to 50% in NH [19, 21, 
22, 24, 81, 83-87], and from 20 to 34% in HNS [15, 16, 88-91]. Two Norwegian 
studies based on patients’ own medication lists report PIMs in 14-18% of older 
patients in general practices [92, 93]. 
Table 2. Explicit prescribing quality indicators (PQI)   
Author 
Year 
(revision) Country Name PQI Description 
Beers [66, 94, 95] 1991 
(1997, 2003) 
USA Beers list Target population aged 65. 
68 criteria; 48 single drugs; 20 drug-disease combinations. 
     
McLeod [96] 1997 Canada McLeods list Target population: not specified. 
38 criteria in four categorises; 
cardiovascular diseases, psychotropics, NSAIDs/other 
analgesics, miscellaneous drugs. 
     
Naugler [97] 2000 Canada IPET Target population aged 70. 
14 criteria; 2 drug specific, 12 drug-disease combinations. 
     
Fastbom, 
Schmidt* [98] 
2010 Sweden Swedish 
National Board 
of Welfares’ 
indicators 
Target population aged 65 (75).  
20 criteria; 9 drug specific criteria, 11 diagnosis-specific 
criteria. 
     
Laroche [99] 2007 France French 
consensus list 
Target population aged 75. 
34 criteria; 29 single drugs/classes; 5 criteria regarding 
specific medical conditions.  
     
Barry [74] 2007 Ireland START Target population aged 65. 
22 criteria of drugs indicated for use. 
     
Gallagher [100] 2008 Ireland STOPP Target population aged 65. 
65 different criteria divided in 10 major criteria;  
7 organ-specific. 2 of drugs regarding side effects; 1 for 
drug duplication. 
     
Basger [75] 2008 Australia Australian 
Prescribing 
Indicators Tool 
Target population aged >65. 
48 drug-disease specific criteria. 
     
Rognstad [77] 2009 Norway NORGEP Target population aged 70. 
36 criteria; 21 single drugs.  15 drug combinations.  
Recommended by authors for use in general practice 
* Project leaders. IPET= mproving Prescribing in the Elderly Tool, START=Screening Tool to Alert doctors to the Right Treatment, 
STOPP=Screening Tool of Older Persons' potentially inappropriate Prescriptions, NORGEP=The Norwegian General Practice criteria, 
NSAIDs=Non-Steroidal Anti-Inflammatory Drugs.  
Although comparison should be done cautiously due to differences in used indicators 
and drug-markets between countries, the proportion of PIMs appears to be higher in 
older Americans than in older Europeans, Table 3. Furthermore, drugs most commonly 
denoted as PIMs vary according to the criteria set used and the population under 
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investigation. Predictors for receiving PIMs comprise female gender, ‘younger’ older 
age (66-70 years) and multiple drug use [101]. A study advocates that patients with 
highest disease burden who are eligible for NH placement but who receive HNS, are at 
highest risk of being prescribed PIMs, compared to other community-dwelling older 
patients or to patients in NHs [102]. The high prevalence of PIMs in different settings 
emphasizes the importance of focusing on prescribing quality in both HNS and NHs.  
Table 3. Potentially inappropriate medication (PIMs) use in older patients  
Author Year Country 
Study 
participants Setting Criteria 
Proportion (%) of  
patients using PIMs 
Strand [92] 1999 Norway Not reported GP Own list* 14  
Dhall [85] 2002 USA 44 562 NH Beers modified* 33  
Nygaard [24] 2003 Norway 1 024 NH Beers modified* 25  
Lau [83] 2004 USA 3 372 NH Beers 50  
Roth [90] 2005 USA 100 HNS* Beers 34  
Fialova [15] 2005 Europe 2 707 HNS Beers* 
McLeod 
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Perri [91]  2005 USA 1 117 NH Beers 47  
Niwata [87] 2006 Japan 1 669 NH Beers 18  
Cannon [16] 2006 USA 786 HNS Beers 31  
Lapane [86]   2007 USA 164 889 NH Beers* 40 
Brekke [93] 2008 Norway 85 836 GP 13 explicit 
indicators 
18  
Hosia-Randell [21] 2008 Finland 1 987 NH Beers 35  
Ryan [103] 2009 Ireland 1 329 GP Beers 
STOPP 
18 
21 
Olsson [22] 2010 Sweden 3 705 NH and 
SCUD 
Swedish National 
Board of 
Welfares’ 
indicators 
* 
Kölzsch [84] 2011 Germany 8 685 NH French consensus 
list 
22  
*See original article for further details. NH=nursing home, HNS=home nursing service, GP=General practice. SCUD=Special Care 
Units for Dementia. 
Drug-related problems 
A range of ‘synonymous’ concepts exist for DRPs and include drug therapy problem, 
medication error, medication related problem, medication therapy problem, treatment 
related problem, therapy related problem and pharmaceutical care issue [104]. 
Different classification systems have been developed to identify, categorise and 
resolve DRPs [105-107]. In 2007 a Norwegian classification system for assessing 
DRPs was published [107]. This classification tool has a hierarchical structure, with 
six main categories (see Table 4), and twelve sub-categories. In this thesis a DRP is 
defined, in accordance to Pharmaceutical Care Network Europe, as “an event or 
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circumstance involving drug therapy that actually or potentially interferes with 
desired health outcomes” [105].   
Table 4. Classification of drug-related problems (DRPs) [107] 
Main category Definitions  
Drug choice One or more drugs are missing according to established national/international guidelines. 
Deviations from guidelines that are based on the patient’s individual treatment goals and risk 
factors are not considered to be DRPs. 
A drug that is seen as unnecessary if the indication is no longer present, with lack of discontinuation 
or double prescription of two or more drugs from the same therapeutic group 
Not given reason for deviation from concordance between drug and diagnosis/indication or 
absolute/relative contraindication because of for example age or co-morbidity. Deviations that are 
based on the patient’s individual treatment goal and risk factors are not considered to be DRPs. 
Dose Suboptimal dosing (including dosing time and formulation) according to established 
national/international guidelines. Deviations that are based on the patient’s individual treatment 
goal and risk factors are not considered to be DRPs. 
Adverse drug reaction Any noxious, unintended, and undesired effect of a drug, which occurs at doses in humans for 
prophylaxis, diagnosis, or therapy (WHO) 
Interaction An interaction is occurring when the effect of a drug is changed by the presence of another drug, 
food, drink or some environmental chemical agent. Drug combinations with intended overall effect 
are not considered to be DRPs. 
Drug use Patients’ real drug use deviate from the doctor’s prescription with respect to type of drug, dose or 
scheme. It is a prerequisite that prescriptions are based on a common understanding (concordance) 
between prescriber and patient (exception: patient with dementia, emergency situation etc.) 
Problems with logistics are not considered to be DRPs. 
Other Monitoring with respect to effect and toxicity of drugs is not done or does not adhere to guidelines. 
In general therapy discussions that include several problems and do not belong in any other 
category. 
DRPs can be identified by performing medication reviews at an individual patient 
level. The performance and comprehensiveness of the review relies on several factors 
including available clinical information, and health personnel’s knowledge and skills. 
Performed systematically in accordance to the DRP classification, the task is time 
consuming and resource demanding. Different health disciplines have conducted 
medication review studies including physicians [108], pharmacists [109] and nurses 
[110].
The first Norwegian study that examined DRPs in NHs revealed problems in 
76% of the patients, with an average of 2.5 DRPs per patient [17]. Other studies have 
reported 4.6 DRPs in older patients consulted in general practices [111], and 2.5-4.0 
DRPs in older NH patients [17, 26, 30, 113], Table 5. 
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Table 5. Drug-related problems (DRPs) in older patients
Author Year Country 
Study 
participants Setting 
DRPs 
per 
patient 
Proportion (%) 
of patients 
With DRPs  
Ruths [17] 2003 Norway 1 354 NH 2.5 77 
Pit [111] 2007 Australia 452 GP - 88 
Finkers [30] 2007 The Netherlands 91 NH 3.5 96 
Stafford [112] 2009 Australia 234 RC 4.6 - 
Kersten [113] 2009 Norway 48 NH 4.0 98 
Davidsson [26] 2011 Norway 93 NH 2.5 88 
Nishtala [114] 2011 Australia 500 RC 2.9 96 
NH=Nursing homes, GP=general practice, RC=Home or  residential care.  
Drugs for treatment of the alimentary, cardiovascular and nervous system are linked to 
the majority of DRPs [114, 115]. Recently two small Norwegian studies have 
addressed DRPs in NHs patients [26, 113]. The majority of problems concerned 
unnecessary drug treatment [113], which in about half of the cases led to drug 
discontinuation [26]. 
Clinical pharmacists and multidisciplinary collaboration  
Clinical pharmacy is according to the European Society of Clinical Pharmacy defined 
as; “a health specialty, which describes the activities and services of the clinical 
pharmacist to develop and promote the rational and appropriate use of medicinal 
products and devices. Clinical pharmacy includes all the services performed by 
pharmacists practising in hospitals, community pharmacies, nursing homes, home-
based care services, clinics and any other setting where medicines are prescribed and 
used” [116]. According to this definition, clinical pharmacy has a wide scope in 
various health care settings. Nevertheless, clinical pharmacy is by many considered to 
be in its modest beginning in Norway. The first program ‘experience-based master's 
degree in clinical pharmacy’ was established in 2009 at the University of Oslo [117]. 
The late onset of clinical pharmacy in Norway can be explained by the fact that the 
only education institution for masters in pharmacy until 1994, the University of Oslo, 
focused mostly on medicinal chemistry and pharmaceutical sciences. Another reason 
is that pharmacists were defined as health personnel as late as in 1999 [118]. Until then 
opportunities to act alongside other health personnel in different settings were limited. 
Pharmacists with responsibility to supervise and monitor drug stocks at institutions 
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were usually not involved in drug therapy decisions or did not participate in 
multidisciplinary teams.  
Twenty years ago Hepler and Strand outlined the re-professionalization and the 
importance for pharmacists to “adopt patient-centred pharmaceutical care as their 
philosophy of practice” [119]. Since then the professional role and opportunity to 
collaborate with other health professions has changed considerably in countries like 
the U.S., Australia, England, Scotland, The Netherlands, but also in Norway. Although 
in its infancy, pharmacists work alongside other health professionals, most at hospitals 
departments, but also in NHs. To the author’s knowledge, multidisciplinary 
collaboration including pharmacists in HNS has not yet been put into the system. 
In 2006 the impact of clinical pharmacists in hospital settings has been 
evaluated in a systematic review. The review concluded that clinical pharmacists 
improved care, with no evidence of harm [120]. Almost at the same time, another 
study evaluated the effect of pharmacist-led medication review on hospital admission, 
mortality and number of drugs prescribed in older patients. This systematic review and 
meta-analysis concluded that pharmacists had no effect on the outcomes, except from 
contributing to a slight decrease in number of drugs prescribed [121].   
In Norway the Government White Paper No. 18, 2004-2005 ‘On course 
towards more correct use of medicine’ emphasized multidisciplinary collaboration 
with pharmacists as one way to achieve quality improvement of older patients’ drug 
therapy [122]. Combined with experience from previous research [17, 123], it is 
important to determine whether pharmacists’ knowledge and skills can be utilized in 
multidisciplinary teams to identify, prevent and resolve DRPs in older patients outside 
of hospitals.  
 The Norwegian Knowledge Centre for the Health Services recently evaluated 
randomized controlled trials aiming to reduce inappropriate drug use in NH [124]. 
Academic detailing, various educational and teaching initiatives, and drug utilization 
reviews performed by pharmacists or GPs have been shown to reduce prescribing of 
psychotropic and other drugs. However, most studies were small and of poor quality 
[124]. Nonetheless, the report highlighted the importance of further research on these 
initiatives.    
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Motivation for the studies and the author’s preconceptions 
In Norway, only a few studies have investigated the pharmacists’ role with regard to 
prevent inappropriate prescribing and to increase the overall quality of drug use for 
older patients. At the moment, pharmacist services are growing in NHs, which 
actualizes research on this topic. Drug utilization studies investigating the quality of 
drug prescribing in HNS are in general lacking. To my knowledge, studies comparing 
medication use and prescribing quality in disease-burdened patients in HNS and NHs 
have not been conducted. With increasing numbers of older persons, and as drug 
consumption is increasing considerably during the last decade (Table 1), it is important 
to develop and implement systems that can improve and maintain prescribing quality 
for these large groups of frail and old patients.  
During my undergraduate study period, I often reflected on the possibilities to 
work clinically with drug-related issues. The pharmacy curricula at the University of 
Tromsø inspired me, and I especially remember visits to hospital wards and 
assessments of patients’ drug regimens. The undergraduate program including patient 
stories and case-based learning encourage a growing interest to work multidisciplinary 
with drug-related issues. By chance during my first job as a consultant pharmacist 
(pharmacist supervision) in Bergen municipality health care service, I met two 
enthusiastic researchers (a physician and a pharmacist) who had experience with 
multidisciplinary collaboration between pharmacists and physicians.  
At the same time, I often wondered at what level in the health care system 
clinical pharmacists could contribute. I developed an interest in the field of drug use in 
older patients, in particular in primary care. Employed by the municipality as a 
consultant pharmacist, I experienced that nurses and physicians whom I had to 
cooperate with in order to improve drug treatment quality perceived me as something 
entirely different, almost as an inspector or a ‘police authority’. This experience 
aroused a curiosity as to how nurses and physicians viewed multidisciplinary 
collaboration with pharmacists as well as changes in the distribution of tasks. 
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AIMS OF THE STUDIES 
The aim of this research was to examine and improve prescribing quality in older 
patients receiving HNS or living in NHs. This has been achieved by conducting two 
comprehensive quantitative studies, and one supplementary qualitative study. The 
three sub-studies had the following aims: 
Paper I  
To examine the quality of drug prescribing for older persons in nursing homes and 
home nursing services based on explicit prescribing quality indicators.  
Paper II 
To describe an innovative team intervention to identify and resolve drug-related 
problems in Norwegian nursing homes. 
Paper III 
To explore how physicians and nurses working in nursing homes and hospitals 
experience multidisciplinary collaboration with pharmacists to optimise drug therapy 
in older patients. 
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MATERIAL AND METHODS  
Design, setting and participants 
Table 6. Design, setting and study participants
Paper Design Setting Population/Informants 
I Analytical 
Cross-sectional 
study; MDD 
database 
Nursing homes and  
home nursing 
services 
11 254 patients  
II Descriptive 
intervention 
study 
Three nursing homes 142 patients 
III Focus group 
and individual 
interviews 
Nursing homes and 
Hospitals 
12 informants;  
4 physicians and 8 nurses  
Paper I 
Drug databases at suppliers (wholesalers) of MDDs in Norway comprise drug use 
information on large numbers of HNS and NH patients. One of the main suppliers was 
contacted and agreed to provide anonymous data for a descriptive cross-sectional 
study. Data extraction was performed on September 9, 2009. All patients 65 years 
were included. The following variables were obtained: age, gender, care setting (HNS 
or NH), drug name, strength, formulation, dosage schedule, regular or p.r.n. use, and 
number of days of dispensed medicines. All drugs were coded according to WHO’s 
Anatomical Therapeutic Chemical (ATC) classification system [23].  
Because of lack of clinical information, patients’ medication lists were screened 
by means of Norwegian explicit quality indicators independent of indications; 
NORGEP [77] was used to identify PIMs, and DRUID [54] for detecting DDIs, 
respectively. The prevalence of drugs use, PIMs, and DDIs was compared between 
care setting (HNS or NH). 
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Paper II  
A descriptive intervention study was conducted. Eligible study participants were 
patients 65 years old in three medium-sized (60-75 beds) NHs in Bergen, Norway, 
using at least one regular drug.  
A pilot study comprising 15 patients was conducted at one NH to test and adjust 
study procedures. Prior to, and during enrolment of study participants, pharmacists and 
the research group met to discuss and clarify ambiguities regarding study procedures. 
Data collection was conducted by three pharmacists from February to July 2006. 
Nurses in charge measured patients’ body weight, blood pressure and pulse, while the 
pharmacists recorded the following data: age, gender, diagnoses, medications (time of 
initial prescribing, brand or generic name, formulation, strength, dosage time, and 
regular or p.r.n. medication), and relevant and available laboratory results. Creatinine 
values recorded in medical charts were entered into the web-based calculator from the 
National Kidney FoundationTM [125] for calculating glomerulus filtration rates. 
Pharmacists performed individual comprehensive medication reviews according 
to a Norwegian classification tool [107], taking into account the gathered information, 
each patient’s clinical characteristics, the Norwegian Drug Formulary [126], the 
Norwegian drug and therapeutic formulary for health personnel [127], DRUID [54], 
and the NHs’ guidelines for drug handling. The pharmacists identified potential DRPs 
and classified them according to the classification tool.   
Multidisciplinary case conferences 
The pharmacists presented the identified potential DRPs to the patients’ physician and 
nurse at the weekly patient-centred case conferences. The clinical team discussed the 
DRPs until consensus was reached: I) team agreed on DRP identified by the 
pharmacist, II) team disagreed, III) team agreed of a DRP being identified, but not 
with the classification of the DRP, and IV) an up till then undiscovered DRP was 
identified during the multidisciplinary team discussion. After agreement on DRPs 
classification, the multidisciplinary team discussed relevant actions to resolve 
acknowledged DRPs. All team members could recommend strategies to achieve 
treatment improvement. The agreed strategy was recorded by the pharmacist. In cases 
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of ambiguities, the physician had the final word. Pharmacists examined whether 
planned interventions were completed by re-visiting the NHs after three weeks. The 
total number of drugs used was recorded before and after the intervention.  
Drugs were coded according to the ATC-classification system [23]. Data was 
analysed with regard to the following outcome measures: DRPs identified by 
pharmacists; DRPs acknowledged, altered, refused or added at case conferences; 
medications involved in DRPs; interventions planned and executed. 
Paper III
Focus group interview and individual interviews are useful for examining peoples’ 
knowledge and experience [128-130]. We applied these two methods to gain 
experience regarding how physicians and nurses had experienced multidisciplinary 
collaboration with pharmacists. NH informants were selected from study sites
described in Paper II. All physicians (three men, one woman) and a purposeful sample 
of six nurses (all women; two from each nursing home) were invited to take part in 
intra-professional focus-group interviews. One of the physicians did not want to 
participate in the focus-group. Furthermore, as one of the remaining physicians was 
prevented from meeting as scheduled, only two physicians (a man and a woman) were 
interviewed for 2 hours. Later, the third physician was interviewed at his office for an 
hour. The nurses’ focus-group interview lasted for 2 hours; one nurse failed to attend 
as planned.  
To contrast findings from NHs, informants for individual interviews were 
recruited from two different hospitals by inviting two chief-physicians, from the 
rheumatology and geriatric departments. Both hospitals were known to include 
pharmacists in the multidisciplinary healthcare team. The purposeful sampling 
intended to include informants who had experienced multidisciplinary collaboration 
with pharmacists over a period of time. Using a semi-structured interview guide an 
experienced moderator with the presence of a secretary (myself), interviewed first the 
NH physicians (n=2) and then the NH nurses (n=5). Later, the author of this thesis 
individually interviewed another NH physician, and the hospital informants, i.e. three 
nurses and one physician. The semi-structured interview guide developed for the 
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purpose covered the following topics: i] personal experience with pharmacist 
collaboration, ii] the impact of the collaboration and iii] the structure of the 
collaboration. All interviews were audio-taped and transcribed (modified verbatim). 
The analysis was performed in accordance with the principles of systematic text 
condensation [131].  
Statistical analysis (Paper I and Paper II) 
Student’s t-test was applied to compare means for continuous data (age, number of 
drugs used, PIMs, DDIs). Chi-square test was applied to compare categorical data 
(gender, settings). Correlation between age, number of drugs used, PIMs and DDIs 
were examined using Pearsons r (one-tailed), Paper I. Logistic regression was 
performed to examine the impact of care setting (NH or HNS) on exposure to selected 
drug groups, PIMs or DDIs, adjusting for patients’ age and gender and number of 
drugs used. Differences were presented as OR with 95% confidence interval (CI), 
Paper I. p-values < .05 were considered statistically significant. The statistical 
package SPSS/PASW version 14/18 was used for data analysis.   
Qualitative analysis (Paper III) 
To facilitate the analysis of the transcribed interviews we used QSR NVivo version 8. 
The analysis process transformed interview material to systematized experience and 
knowledge. As premise for the analysis procedure we used the objective of the study, 
clarified our self-known presuppositions in the field and made an active choice of 
theory basis [132, 133]. These premises clarified, the material (transcripts) was read by 
all the authors, searching for an understanding of the data within our frame of 
reference. Thus we identified an initial set of themes and consented on the following: 
resources, quality changes, awareness and change of behaviour, professional 
knowledge, and multidisciplinary collaboration. The material was searched from the 
perspective of these themes, selecting text elements (units of meaning) that specifically 
represented them. These units of meaning were de-contextualized and analogous units 
were grouped under abstracted headings and expressed in generalized descriptions. 
Using these categories as a framework, we searched all material for additional 
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perspectives on the core items. These were: i] introduction of a new team member, ii] 
consequences for the collaborating health personnel and their patients and iii] 
perspectives on collaboration development.  
Ethics and approvals 
All three studies were presented to the Regional Committee for Medical Research of 
Western Norway; no objections were put forward. In addition, the Norwegian Social 
Science Data Services gave their approval. The required exemption of professional 
secrecy was given by the Norwegian Data Inspectorate and the Norwegian Directorate 
for Health and Social Affairs, Paper II.   
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SYNOPSIS OF THE PAPERS  
Paper I 
Prescribing quality for older people in Norwegian nursing homes and home 
nursing services using multi-dose dispensed drugs. 
Halvorsen KH, Granas AG, Engeland A, Ruths S. Pharmacoepidemiol Drug Saf 2011. 
Objective To examine the quality of drug prescribing for older persons in nursing 
homes and home nursing services based on explicit prescribing quality indicators.  
Methods and material Cross-sectional study comprising NHs and HNS patients aged 
65 years using MDD. PIMs were identified according to NORGEP criteria, and DDIs 
according to DRUID. The impact of care setting on exposure to selected drug groups, 
PIMs and DDIs was calculated, adjusting for patients’ age, gender, and number of 
drugs used.  
Results Altogether 11 254 patients were included, 2 986 (72% women, 85.3 years) in 
NHs and 8 268 (69% women, 83.0 years) receiving HNS. In total, 63 936 drug items 
were analysed. Patients in NHs and HNS used on average 5.7 regular MDD. Drugs for 
treatment of cardiovascular (79.6%), nervous (68.9%), alimentary (57.1%) and blood 
(56.5%) system conditions were most frequently prescribed. Figure 4 presents the ten 
most commonly used MDDs. As compared to NHs, more patients in HNS used 
cardiovascular drugs and fewer used psychotropic drugs. 
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Figure 2. Top ten prescribed multi-dose dispensed drugs to nursing home and 
home nursing service patients in Norway 2009 
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Altogether 26% of the patients used at least one PIM, 31% in NHs and 25% in HNS 
(p<.001). Concomitant use of three or more psychotropic and/or opioid drugs was the 
criterion most commonly identified in both NHs (18%) and HNS (9%) (p<.001). The 
mean number of PIMs was significantly correlated with numbers of drugs used 
(p<.01).  
A total of 8 615 DDIs were identified in 55% of patients, 48% in NH and 57% 
in HNS (p<.001). The mean number was 0.77 DDIs per patients. The number of DDIs 
was significantly correlated with the number of drugs used (p<.01). DDIs were 
assigned severity level A, B, C and D in 27%, 39%, 9% and 2% of all patients, 
respectively.  
Conclusions PIMs were more often prescribed to patients in NHs, while patients in 
HNS were more frequently exposed to DDIs. There are significant differences in the 
quality of drug prescribing in NHs compared to HNS.  
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Paper II 
Multidisciplinary intervention to identify and resolve drug-related problems in 
Norwegian nursing homes  
Halvorsen KH, Ruths S, Granas AG, Viktil KK. Scand J Prim Health Care 2010; 28: 
82-88.
Objective To describe an innovative team intervention to identify and resolve DRPs in 
Norwegian NHs. 
Methods and materials Descriptive intervention study in three NHs in Bergen, 
Norway. DRPs were identified by pharmacists, and discussed with patients’ physician 
and nurse at multidisciplinary case conferences. Actions to resolve the DRPs were 
planned and followed-up. 
Results Three pharmacists systematically reviewed 142 long-term care patients (106 
women, 86.9 years) which most commonly suffered from dementia (65%), 
hypertension (35%) and depression (34%). The ten most commonly used regular and 
p.r.n. medications are presented in Table 7. Pharmacists identified 719 potential DRPs, 
of which 372 were accepted, 104 accepted but reclassified, 243 rejected, and 28 new 
DRPs added at case conferences; finally, 504 DRPs were acknowledged. Within three 
weeks 476 (94%) of the DRPs were resolved. The two most frequently identified 
DRPs were “Unnecessary drug” (n=194) and “Monitoring required” (n=68). Drugs for 
treatment of the alimentary and nervous system accounted for the majority of the 
DRPs. The intervention resulted in a significant mean reduction of 1.5 prescribed 
drugs per patient (p<.01).  
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Table 7. The ten most commonly prescribed regular and p.r.n. medications  
to nursing home patients (n=142) 
Regular medications P.r.n. medications 
ATC code Generic name % ATC code Generic name % 
A06AD11 Lactulose 81 N02BE01 Paracetamol 89 
N02BE01 Paracetamol 58 N05BA04 Oxazepam 46 
B01AC06 Aspirin 55 N02AA59 Paracetamol + codeine 29
B03BA03 Hydroxycobalamin 47 N05CF01 Zopiclone 26 
C03CA01 Furosemide 39 N02AX02 Tramadol 22 
A06AB02 Bisacodyl 28 N05BA01 Diazepam 21 
N05CF01 Zopiclone 33 A03FA01 Metoclopramide 19 
A11EA- Vitamin B-complex 32 C01DA02 Glyceroltrinitrate 19 
N05BA04 Oxazepam 25 A06AG11 Sodium lauryl sulfate 14 
A06AB04 Citalopram 24 A06AB02 Bisacodyl 13 
Conclusions The multidisciplinary team intervention was suitable to identify and 
resolve DRPs in NHs. Systematic medication reviews and involvement of pharmacists 
in clinical teams should therefore be implemented on a regular basis to achieve and 
maintain high quality drug therapy.  
Paper III  
Physicians’ and nurses’ experiences of multidisciplinary collaboration with 
pharmacists at case conferences – A qualitative study.  
Halvorsen KH, Stensland P, Granas AG. Int J Pharm Pract 2011; 19: 350-57. 
Objective To explore how physicians and nurses working in NHs and hospitals 
experience multidisciplinary collaboration with pharmacists to optimize drug therapy 
in older patients. 
Methods and material Qualitative interview study, i.e., focus group and individual 
interviews, using systematic text condensation. Four physicians and eight nurses from 
NHs (long-term care) and hospital wards (rheumatology and gerontology) were 
interviewed.  
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Results 
Introduction of a new team member 
Health professionals had different perceptions about collaborating with pharmacists. 
Lack of a predictable time schedule and knowing what the focus was supposed to be at 
case conference caused some frustration for collaborating health personnel. The 
informants reported that pharmacists addressed most of the identified problems 
towards the physician rather than nurses. The physicians found it challenging to cope 
with questions demanding clear professional answers regarding established drug 
therapy, regardless of them being responsible for initiating treatment or not.    
Consequences for the collaborating health personnel and their patients 
The introduction of pharmacists to the multidisciplinary team changed focus from 
other care issues towards drug therapy issues to a greater extent than before. 
Consequently, this led to less attention for discussing nurse-related issues, and caused 
time strain for the nurses who experienced that their issues were partly unresolved 
after the case conferences. Nevertheless, according to the informants the process of 
addressing DRPs resulted in raised awareness on the quality of prescribing, which was 
considered to outweigh the downsides of other issues given less attention. 
Perspectives on collaboration development  
The informants had different opinions about how often pharmacists ought to 
participate at case conferences. While some suggested twice annually, others felt it 
was important to have pharmacists present continuously. The way pharmacists 
independently collected data and performed medication reviews prior to case 
conferences was endorsed by the informants as it required less input from them. The 
hospital nurses felt that pharmacists’ findings, mostly concerning drug treatment 
decisions, could be raised directly with the physician without their attendance. In 
contrast, NH nurses felt that their presence was important, and thus wanted to actively 
take part in the multidisciplinary team when discussing patients’ drug treatment. 
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Conclusions Physicians and nurses valued the pharmacists’ services and reported that 
this collaboration improved patients’ drug therapy. However, before implementing this 
service in NHs, there is a need to make an organisational frame for this collaboration 
to support the professional role of the pharmacist.
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DISCUSSION
Discussion of results 
Number of drugs used by older patients in NH and HNS (Paper I and II) 
In Paper I we report an average of 5.7 regular drugs among MDD users, whereas 
Paper II including all drugs revealed 8.1 regular drugs, respectively. Compared with 
other studies, our findings suggest that the total number of drugs used per patient in 
NHs has increased during the last decades. A Norwegian study examining DRPs in 
1 552 NH patients in 1997 revealed a mean of 5.0 drugs regular medications [17]. Our 
study revealed 8.1 regular drugs and concurs well with other Nordic studies reporting 
an average of 7.5-8.5 regular drugs [21, 22, 26], although caution should be exercised 
when comparing the total number of drugs used across borders due to differences in 
therapy traditions, study populations and health care systems.  
In Paper I the number of prescribed MDD was equal in HNS and NH patients. 
As mentioned earlier, drug utilization studies from HNS are sparse. The Ad-HOC 
project (2000-2003) including 2 707 HNS patients in eight European countries 
revealed that 92% (of N=388) of older Norwegian HNS patients used 1 drug, 34% 
used 6 drugs, and 11% used 9 drugs, respectively [15]. The data comprised patients’ 
drug use during one week including regular, p.r.n. and over-the-counter medications.  
The increasing numbers of drugs used can possibly be explained by i] focus on 
preventive care such as anti-platelet therapy, lipid-lowering drugs and blood pressure-
lowering drugs, ii] adherence to prescribing guidelines recommending complex drug 
regimens for e.g. cardiovascular diseases, and iii] availability of new treatment 
alternatives. Although these explanations in most cases may benefit the patients, it also 
puts high demands on prescribers and health care professionals to evaluate and 
monitor drugs’ effects and ADRs.  
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Drug utilization patterns in HNS and NH (Paper I) 
Drug utilization patterns varied between HNS and NHs, Figure 5; mainly due to 
differences in use of cardiovascular and psychotropic and/or opioid drugs. Dementia 
and BSPD are known predictors for institutionalization [12], and subsequent 
prescribing of psychotropic drugs for symptomatic treatment [134]. On the other hand, 
use of -blockers and diuretics varied little between the two settings, suggesting that 
cardiovascular diseases are highly prevalent also in NHs.   
Lipid-lowering drugs were the drugs accounting for the greatest differences 
between patients in HNS and NHs, Paper I. The variation may be explained by 
adherence to guidelines that advise against prescribing to patients whose life 
expectancy is less than five years [10, 74]. In general, drug discontinuation is 
considered appropriate when time to effect is longer than predicted life expectancy 
[135]. But when it comes to lipid-lowering drugs, controversy exists whether to 
discontinue the drug or not. While the effect of lipid-lowering drugs in secondary 
prevention is well-known, their role in primary prevention is questioned [136, 137]. In 
addition, prescribing physicians need to consider ADRs, DDIs, costs and number 
needed to treat to prevent one new incident of cardiovascular disease [138]; a 
demanding task in older patients with a range of co-morbidities using multiple drugs. 
Moreover, the role of primary prevention in the NH setting is limited, and attention 
should instead be devoted to palliation.       
    
Quality of drug prescribing in older patients 
To determine the quality of drug prescribing, PIMs, DDIs (Paper I) and DRPs (Paper 
II) were used as outcome measures. Findings in both papers indicate a need for 
prescribing quality improvements. Based on explicit criteria, 25% of older patients 
receiving MDD were exposed to PIMs, Paper I. The proportion was higher in NH 
patients compared to those in NHs (31% vs. 25%, respectively). However, when 
NORGEP criterion no. 36 (three or more psychotropics and/or opioid drugs) was 
excluded differences between HNS and NHs disappeared (21% in both settings). 
Several former studies have identified sub-optimal quality of psychotropic drug use, in 
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particular in NHs [17, 21]. Our findings suggest that prescribing quality in NHs still 
needs improvement [24, 139].  
A two-fold prevalence of concomitant use of three or more psychotropic drugs 
and/or opioid drugs was found in NHs compared to HNS, Paper I (18% vs. 9%, 
respectively). Recently, the prognostic value of this criterion has been questioned 
[140]; In long-term care facilities, mortality risk at 5-years follow-up did not differ 
between older patients using 2 vs. 3 psychotropic drugs, but risk was higher in 
psychotropic drug users vs. non-users in community-dwelling older persons with 
dementia [141]. However, it is important to keep in mind that the indicator was 
intentionally developed to prevent undesirable ADRs such as muscular weakness, 
falls, fractures, cognitive impairment, or DDIs, and not hard endpoints like mortality 
[77]. The fact that patients in HNS only have visits from health personnel on demand, 
while NH patients have continuous surveillance outline the importance of addressing 
multiple psychotropic drug use in this setting as well. This can be achieved by taking 
advantage of the possibilities in the computerised MDD system, but so far the 
possibilities inherent in electronic prescribing support have been neglected. The 
potential of incorporating alerts, for instance by using explicit criteria [77], and of feed 
back to GPs have existed for more than ten years [142]. Although the method 
contributes to reduce PIMs [142], the technology has only been used for feedback 
regarding DDIs from pharmacies (manually – telephone calls) to physicians in 
Norway. Finally, the Norwegian Medicines Agency has now taken responsibility and 
has developed the program “prescribing and dispensing” support (FEST). FEST 
provides identical up-to-date drug information both to prescribers in different clinical 
settings and drug dispensers [143].    
The far more comprehensive method used to investigate DRPs revealed that 
most problems concerned unnecessary drug use; this finding gave rise to a significant 
reduction of 1.5 prescribed drugs per patient, Paper II. Former studies have shown 
that medication reviews can contribute to reduce total drug consumption [121]. In this 
study, almost all patients (>98%) had DRPs. Alimentary and nervous system drugs 
caused the majority of acknowledged DRPs; corresponding with findings from a 
Dutch NH study where DRPs identified in 96% of the patients mostly constituted 
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‘unknown indications’; subsequently leading to drug discontinuation [30]. Compared 
to the BEDNURS study which identified DRPs in 75% of patients [17], our and other 
recent studies [26] suggest a decrease in quality of drug treatment during the last years, 
as the proportion of DRPs in NHs has increased. However, in the BEDNURS study 
less clinical information was available, like for instance laboratory values and body 
weight. Neither did they discuss potential DRPs with the patients’ physician. 
Positively, in Paper I less than 3% of patients in both NH and HNS used 
diazepam or nitrazepam. A former Norwegian study revealed that 22% of NH subjects 
used benzodiazepines [144]. In addition, NSAIDs were prescribed to less than 4% 
(result not published), while reported to be issued to 7% of older patients in general 
practice in harmful combination with other drugs [93].     
In contrast to the substantial use of psychotropic drugs in NHs, Paper I, ADRs 
were almost not identified, Paper II (< 1%). This questions whether the broad 
approach undertaken in Paper II turned out to focus on selected areas like over-
treatment, i.e., unnecessary drug use. The argument is also supported by the fact that 
under-treatment, reported to be a prevalent problem in NHs [17, 145], was only 
identified in four patients.      
We conducted a comprehensive screening for DDIs by using DRUID [54], and 
identified 1% severe (class D) DDIs in NH patients and 2% in HNS patients, Paper I. 
For comparison, a Swedish study of older NH patients using in average 8.5 regular 
drugs reported class D DDIs to comprise 8.1 % of patients [22]. In Finland, 4.8% of 
older NH patients using 7.9 regular drugs per day were susceptible to class D DDIs 
[21]. The use of MDD data, excluding drug groups such as warfarin and anti-infectiva, 
may explain the lower prevalence of clinical significant DDIs identified in our study, 
and make direct comparison difficult. Surprisingly, HNS patients were more often 
exposed to DDIs (any class) than NH patients; putting them at a higher risk of 
experiencing ADRs. Furthermore, the result raises questions if the DDIs screening 
process of MDD performed in pharmacies is performed properly. The difference may 
also be explained by poor communication lines and/or collaboration between 
prescribers and dispensers, or that GPs take DDIs into higher consideration when 
initiating drug therapy in frail and vulnerable NH patients.      
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Multidisciplinary collaboration involving pharmacists  
Many studies have demonstrated sub-optimal prescribing quality in older patients [21, 
93, 103]. Patients’ GPs are responsible for overall prescribing quality, but strive of 
different reasons to achieve desirable quality. Pitfalls are many and explanations are 
partly related to diagnostic work and whether assimilated information regarding drug 
therapy is used appropriately [146]. In order to improve the quality of medical care for 
NH patients, the Norwegian Medical Association has decided to establish a special 
competence area for NH medicine in 2011 [147]. 
 We investigated whether pharmacists could contribute to improve the quality of 
drug prescribing for older patients, in cooperation with patients’ physicians, Paper II 
and III. The methodology applied in Paper II allowed a comprehensive review of the 
individual patient’s medication list to identify DRPs. When pharmacists presented 
findings at case conferences, the physician in particular was enquired to reconsider 
prescribing decisions. A series of questions, and drug treatment discussions enabled 
evaluation of existing drug therapy, thus fulfilling one of the premises for good 
prescribing [146].  
However, Paper III describes how the physicians experienced challenges when 
being questioned by pharmacists, a phenomenon also observed by the nurses; 
demonstrating the novelty of multidisciplinary collaboration involving pharmacists. 
The importance of clarifying roles prior to implementing a pharmacist-physician 
collaboration has previously been described [148], and one of the GPs outlined the 
importance of not presenting prescribing errors in a condescending way; thus 
humiliating other team members.   
In Norway, during the last ten years pharmacists have adapted a patient-centred 
service in the hospital setting [149, 150], and clinical pharmacists are now even 
employed at smaller local hospitals. Recently in Sweden, the implementation of a 
comprehensive pharmacist service for patients 80 years and older in this setting has 
shown to reduce morbidity and health care costs [151].  
To improve prescribing quality in NHs, we recommended implementing 
medication reviews and multidisciplinary collaboration with pharmacists, Paper II, an 
intervention endorsed by both physicians and nurses in Paper III. However, there is a 
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need to consider which patients in NHs (or HNS) should be prioritized for medication 
reviews and multidisciplinary discussion. It will also be necessary to consider when, 
and how often reviews should be conducted. In the U.S., medication reviews 
performed every third month by clinical pharmacists in NH facilities became 
mandatory through the Omnibus Budged Reconciliation Act in 1987. The frequency 
was later increased to monthly [148, 152]. A stepwise model, starting at the system 
level with explicit quality indicators [100] could be a useful approach as demonstrated 
in Paper I. For instance, suppliers of MDD could easily implement such a service and 
give feedback regularly to prescribers. Then, an individual approach like the model 
demonstrated in Paper II could be implemented. Currently, the Norwegian Directorate 
of Health is working on a guide for medication reviews in different health care 
settings.   
The pharmacists (Paper II) did not interview the patients about their problems 
related to drug use; an approach which has been used in the hospital setting to identify 
DRPs [153]. The high prevalence of dementia in the NH setting [9] makes patient 
interviews difficult. When interviewing hospital nurses (Paper III), they at times felt 
redundant when physicians and pharmacists discussed drug therapy strategies. In 
contrast, the NH nurses experienced their presence as important, because of their 
profound patient knowledge; affirming the importance of adjusting collaboration 
models to the relevant health care setting. 
The rather positive evaluation in Paper III and the results from Paper II
propose to reconsider how to utilize the skills and competence of pharmacists. The 
multidisciplinary team including three different health professions discussed and 
judged to what extent potential DRPs were real DRPs. Furthermore, relevant actions 
were planned and carried out to resolve the acknowledged DRPs; implying that the 
multidisciplinary team managed to collaborate, and hence improved overall 
prescribing quality by reducing DRPs.  
Comprehensive systematic medication reviews demand clinical information 
There has been a growing interest from pharmacy chains during the last years to 
conduct medication reviews. Studies have questioned the effect of home based 
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medication reviews on reducing hospitalization, but findings are conflicting [154, 
155]. In Norway accessibility to medication records outside the institutional setting is 
not catered for, meaning that medication reviews as performed in Paper II are not 
possible to conduct outside the NHs or the GP’s office. As demonstrated in Paper II, 
accessibility to patient medical records as well as the physicians’ clinical input and the 
nurses’ profound patient knowledge are essential to perform comprehensive 
medication reviews. This underlines the importance of developing collaboration 
models which bring together these three health professions in the respective settings. 
These models should also focus on improving collaboration between physicians, 
nurses and pharmacists [155].         
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Methodological considerations 
The term validity is normally divided into internal validity; describing whether the 
method is applicable to obtain valid knowledge about the studied phenomenon, and 
external validity; dealing with transferability [132]. This section addresses 
methodological aspects individually for each paper.
Paper I 
To my knowledge, this is the first Norwegian study using MDD data to assess 
prescribing quality for patients in HNS and NHs. Performing ‘large-scale’ drug 
utilization studies in HNS and NH patients has previously been difficult due to the lack 
of prescription databases for the NH setting, and the fact that patients receiving HNS 
cannot be identified in the Norwegian national prescription database [65]. The study 
comprised numerous HNS and NHs throughout the country. Patients’ age and gender 
distribution was in concordance with the general HNS and NH population in Norway 
(SSB), which contributes to external validity.  
The MDD database includes some information of other drug formulations than 
tablets and capsules. However, because of uncertainty regarding the quality of these 
data we decided to exclude them from the analysis. P.r.n. medications were excluded 
for the same reason. This systematic selection bias was leading to a certain 
underestimation of total drug use, PIMs and DDIs.  
Assessment of prescribing quality by using the explicit Norwegian quality 
indicators NORGEP [77] and DRUID [54] was considered advantageous as they 
correspond to the National Drug formulary [126]. On the other hand, NORGEP 
addresses only a short list of drugs considered inappropriate in older patients [77], 
while all other medications are by default considered appropriate. Further, neither 
over- nor under-prescribing could be identified, e.g. too low dose of paracetamol for 
pain management. Additionally, we know that off-label prescribing occurs, and that 
physicians in special cases may choose to prescribe ‘inappropriate’ drugs; illuminating 
the problem of lacking clinical information. 
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Concerns have been raised about explicit quality indicators’ appropriateness to 
determine the quality of drug prescribing [76, 140]. Ideally, quality indicators should 
be validated in the actual setting before use [156]. However, the NORGEP criteria are 
recommended, but not validated by their authors for use in the NH setting [77].      
Paper II 
The relatively small number of included patients (N=142) and NHs (N=3) is a 
limitation to the external validity of the study. Moreover, we cannot rule out a certain 
selection bias, as the process of including study participants was left to the 
collaborating NHs’ physicians and nurses. 
Internal validity was strengthened by performing a pilot study on 15 patients to 
adjust study procedures, and a midterm meeting with data collectors and researchers to 
monitor and discuss the entry of data. Further, the DRP classification system provided 
the structure for the systematic medication review, and served as a platform for 
discussing the identified DRPs in patients [107]. Although the clinical skills and 
knowledge of the GPs will probably affect the accuracy of classification positively, we 
did neither examine the individual pharmacists’ identification or classification of 
DRPs, nor the multidisciplinary groups’ agreements. A way to increase the accuracy of 
DRP classification, and thus validity, is to present the problems to a group of experts 
for rating; similar to the method used to develop the DRP classification system [107]. 
However, such a process is impractical to conduct in a busy clinical setting where the 
classification of DRPs should be a secondary consideration. Priority should be given to 
identify and acknowledge that a problem actually exists and then perform relevant 
actions.  
Paper III  
Being a novice qualitative researcher this study has limitations and strengths that need 
to be address more comprehensively.  
Sampling, or the selection of informants for the study, is a critical point in 
qualitative research. Mays describe that the researcher does not seek a random or a 
representative sample of the population, but a strategic one, which may be able to 
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describe the phenomenon under investigation in great detail [157]. As 
multidisciplinary collaboration with pharmacists, particularly in NHs, is at an early 
phase in Norway, there is not a vast pool of informants to choose from. One could 
argue that the study design was not optimal as we were only able to conduct the focus 
group interview with the nurses, and not with the physicians. Furthermore we did not 
investigate the experiences of pharmacists, nor conducting multi-professional focus 
group interviews. Both alternatives would have contributed to more data and most 
likely a broader understanding of the studied phenomenon. However, systematic 
empirical knowledge has its own value [158] and we only aimed to achieve early 
experiences and perspectives of this collaboration.  
Data collection was performed by using both a semi-structured focus group and 
individual interviews. The use of open-ended questions in both focus group interviews 
and individual interviews allow the interviewer and the interviewees to follow ideas 
regarding the area under exploration [68]. However, in focus group interviews, group 
dynamics also plays an important role to bring out knowledge. Both methods may gain 
insight into the informant's own experiences, thoughts and feelings [128, 159].  
The phenomenon of transcribing speech to text, and further translating from one 
written language to another, may introduce ambiguities or errors. Kvale considers 
audio-taping to cause the first abstraction [130]. The importance of transcripts being 
close to verbatim have been outlined, and several types of transcribing errors have 
been described [160], including: i] deliberated alterations; consisting of tiny text 
adjustments to bring out the meaning better, ii] accidental alterations; providing the 
text a different meaning than originally intended, and iii] loss of non-verbal 
communication, i.e., body language. In this paper the entire transcribing process was 
performed by the same researcher, who was present during all interviews. This ensured 
equal transcribing from audio-tape to text, and the opportunity to take into account 
aspects from the interviews and group dynamics in the analytical process [130]. 
However, danger of nuances and information being lost in translation is always 
present, thus affecting reliability.   
Reliability concerns also whether findings may be reproduced by other 
researchers based on the same data, or at later moments [130]. In our case pharmacists 
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acted as interviewers. If a nurse or a physician, both with alternative preconceptions 
compared to pharmacists (and myself), had conducted the interviews other ideas and 
perspectives reflecting their own professions may have been followed and explored 
more extensively. However, in qualitative research repeatability is rarely a relevant 
criterion for ensuring reliability [132]. Instead, it is of interest to exploit the diversity 
in qualitative data [161].        
When it comes to validity, Kvale describe a seven step process permeating the 
whole research process from theory basis to whether the main findings are reported 
consistently. The work of validation should be conducted continuously and not only at 
the end of knowledge production [130]; most likely why “qualitative analysis should 
not be left to the novice” [162]. By having two experienced (physician and pharmacist) 
and one novice researcher (myself) to perform the analysis and interpretation of 
findings, the reported findings were balanced according to the investigators different 
preconception and enabled mirror of true experiences. However, both internal and 
external validity might have benefited from including a nurse in the research and the 
analytical process; thus better ensuring investigator triangulation [163]. A more 
thorough work to ensure that all informants met as scheduled, might by providing a 
richer material also have increased the validity.      
Member validation, i.e., selecting one or more of the respondents to read the 
transcripts or just an abstract of them, is another way to promote validity [164]. This 
method gives the interviewees the opportunity to confirm or disapprove the 
interpretations of findings. In our case, the two interviewers summarized thoughts and 
perspectives to some extent during or at the end of the interviews. But the respondents 
were not invited to respond to our interpretations, a step that may have strengthened 
validity. However, such a procedure is demanding [164], and brings both advantages 
and disadvantages [165]. 
In my experience, the role of the qualitative researcher has been the most 
difficult to account for or to describe. Awareness of own preconceptions and to take 
them into consideration during the entire research process is important [132]. As 
described in the explanations of my preconceptions, I feared that the role as a 
pharmacist in the multidisciplinary team (but also as a researcher) would be misjudged 
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by the other collaborators. The collection of data to Paper II and III revealed, 
however, something different. The interest and willingness to share own experiences, 
and the collaborators’ interest to improve the quality of drug treatment differed from 
what I initially perceived. Still, as described in the preconceptions and in Paper III, 
readers of this thesis and Paper III need to take into consideration my motivation of 
developing clinical pharmacy.     
External validity deals with whether findings or experiences can be transferred 
to other settings than they were obtained in [132]. As multidisciplinary collaboration is 
in an early phase in Norway, and problems with sampling were experienced, we 
decided to contrast our findings from nursing homes with findings from hospitals. 
Collecting experiences from two settings rendered possible comparison between them. 
Although the experiences varied to some degree for some themes, similarities were 
also revealed; thus serving as a test for external validity.       
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IMPLICATIONS AND FURTHER RESEARCH 
This thesis demonstrates the need of improving prescribing quality for older patients in 
HNS (Paper I) and NHs (Paper I and Paper II). Based on a system audit of drug 
treatment in NHs, the Norwegian Board of Health has pointed out that improving 
structures and systems is a prerequisite for providing good quality drug treatment [62]. 
With the imminent increase in number of older patients, quality system should be 
implemented to improve and maintain prescribing quality.  
Paper II reveals that a multidisciplinary collaboration model involving 
pharmacists is eligible to identify and resolve DRPs in NHs. This finding is supported 
by a preliminary evaluation of ‘In Safe Hands: the Norwegian patient safety campaign 
2011 – 2013’ [166]. However, signals from the national health authorities are 
contradictory; while the White paper “On course towards more correct use of 
medicine” [122] recommends multidisciplinary collaboration with pharmacists, one of 
the focus areas in the Norwegian patient safety campaign; “Proper use of medicines in 
nursing homes” was originally planned conducted without pharmacists.   
 Physicians’ and nurses’ experience of collaborating multidisciplinary with 
pharmacists, Paper III, are largely positive. Both physicians and nurses expressed that 
pharmacists were able to give constructive feedback and aided synergistically in the 
multidisciplinary team to improve quality of prescribing and drug utilization in NH 
patients. 
  This thesis advocates for change in strategies to improve prescribing quality. 
The availability of a national tool kit comprising both explicit and implicit methods 
can facilitate the work of physicians, nurses and pharmacists. We also need to ensure 
that prescribing quality is maintained when patients are transferred between health 
care levels, in particular on implementation of the Coordination reform [42]. 
Electronic prescriptions (eResept) [167] and FEST [143] provide opportunities to 
implement guidelines and provide feedback.  
 Further research should concentrate on the impact of medication reviews on 
clinical outcomes such as quality of life, ADRs, hospital admissions and mortality. 
Furthermore, it is important to examine when and how often medications reviews 
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should be conducted. Findings in Paper I imply the need of performing more 
comprehensive prescribing quality studies among patients receiving HNS. These 
patients have a high disease burden, and most of them use multiple drugs; I propose to 
investigate a multidisciplinary collaboration model including GPs, nurses and 
pharmacists in this setting as well.   
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